Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3394-3400

  Van Duin, David ^a   Casadevall, Arturo ^a   Nosanchuk, Joshua D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LACCASE; LEVODOPA; MELANIN;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DILUTION; DRUG BINDING; DRUG EFFICACY; FUNGUS ISOLATION; HISTOPLASMA CAPSULATUM; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; HISTOPLASMA; MELANINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING;

EID: 0036840642     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3394-3400.2002     Document Type: Article

References (39)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338.
2. Avramidis, N., A. Kourounakis, L. Hadjipetrou, and V. Senchuk. 1998. Anti-inflammatory and immunomedulating properties of grape melanin. Inhibitory effects on paw edema and adjuvant induced disease. Arzneimittelforschung 48:764-771.
3. Bouffard, F. A., R. A. Zambias, J. F. Dropinski, J. M. Balkovec, M. L. Hammond, G. K. Abruzzo, K. F. Bartizal, J. A. Marrinan, M. B. Kurtz, D. C. McFadden, et al. 1994. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J. Med. Chem. 37:222-225.
4. Buchanan, K. L., and J. W. Murphy. 1998. What makes Cryptococcus neoformans a pathogen? Emerg. Infect. Dis. 4:71-83.
5. Casadevall, A., A. L. Rosas, and J. D. Nosanchuk. 2000. Melanin and virulence in Cryptococcus neoformans. Curt. Opin. Microbiol. 3:354-358.
6. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:1029-1033.
7. Doering, T. D., J. D. Nosanchuk, W. K. Roberts, and A. Casadevall, 1999. Melanin as a potential cryptococcal defence against microbicidal proteins. Med. Mycol. 37:175-182.
8. Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158:790-799.
9. Franzot, S. P., J. Mukherjee, R. Cherniak, L. C. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89-97.
10. Ghannoum, M. A., A. S. Ibrahim, Y. Fu, M. C. Shafiq, J. E. Edwards, Jr., and R. S. Criddle. 1992. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J. Clin. Microbiol. 30:2881-2886.
11. Graybill, J. R. 1988. Histoplasmosis and AIDS. J. Infect. Dis. 158:623-626.
12. Hajueh, R. 1995. Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 1):S108-S110.
13. Hajjeh, R. A., P. G. Pappas, H. Henderson, D. Lancaster, D. M. Bamberger, K. J. Skahan, M. A. Phelan, G. Cloud, M. Holloway, C. A. Kauffman, and L. J. Wheat. 2001. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin. Infect. Dis. 32:1215-1220.
14. Hill, Z. H. 1992. The function of melanin or six blind people examine an elephant, Bioessays 14:49-56.
15. Kaliszan, R., A. Kaliszan, and I. W. Wainer. 1993. Prediction of drug binding to melanin using a melanin-based high-performance liquid chromatographic stationary phase and chemometric analysis of the chromatographic data. J. Chromatogr. 615:281-288.
16. Kohler, S., L. J. Wheat, P. Connolly, C. Schnizlein-Bick, M. Durkin, M. Smedema, J. Goldberg, and E. Brizendine. 2000. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 44:1850-1854.
17. Kozel, T. R. 1995. Virulence factors of Cryptococcus neoformans. Trends Microbiol. 3:295-299.
18. Kurtz, M. B., C. Douglas, J. Marrinan, K. Nollstadt, J. Onishi, S. Dreikorn, J. Milligan, S. Mandala, J. Thompson, and J. M. Balkovec. 1994. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother. 38:2750-2757.
19. Kwon-Chung, K. J. I. Polacheck, and T. J. Popkin. 1982. Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J. Bacteriol. 150:1414-1421.
20. Larsson, B. S. 1993. Interaction between chemicals and melanin. Pigment Cell Res. 6:127-133.
21. Lopez-Jodra, O., J. M. Torres-Rodriquez, R. Mendez-Vasquez, E. Ribas-Forcadell, Y. Morera-Lopez, T. Baro-Tomas, and C. Alia-Aponte. 2000. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method. J. Antimicrob. Chemother. 45:645-649.
22. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcus in the era of AIDS - 100 vents after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
23. Mohagheghpour, N., N. Waleh, S. J. Garger, L. Dousman, L. K. Grill, and D. Tuse. 2000. Synthetic melanin suppresses production of proinflammatory cytokines. Cell. Immunol. 199:25-36.
24. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. Nosanchuk, J. D., and A. Casadevall. 1999. Amphotericin B: activity beyond fungal cell sterols. Recent Res Dev. Antimicrob. Agents Chemother. 3:7-15.
26. a. Nosanchuk, J. D., B. L. Gomez, S. Youngchim, S. Diez, P. Aisen, R. M. Zancope-Oliveira, A. Restrepo, A. Casadevall, and A. J. Hamilton. 2002 Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect. Immun. 70:5124-5131.
27. Nosanchuk, J. D., R. Ovalle, and A. Casadevall. 2001. Glyphosate inhibits melanization of Cryptococcus neoformans and prolongs survival of mice after systemic infection. J. Infect. Dis. 183;1093-1099.
28. Nosanchuk, J. D., A. L. Rosas, and A. Casadevall. 1998. The antibody response to fungal melanin in mice. J. Immunol. 160:6026-6031.
29. Nosanchuk, J. D., A. L. Rosas, S. C. Lee, and A. Casadevall. 2000. Melanisation of Cryptococcus neoformans in human brain tissue. Lancet 355:2049-2050.
30. Ren-Kai, L., M. A. Ciblak, N. Nordoff, L. Pasarell, D. W. Warnock, and M. R. McGinnis. 2000. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44:1734-1736.
31. Robinson, P. A., M. Bauer, M. A. E. Leal, S. G. Evans, P. D. Holtom, D. M. Diamond, J. M. Leedom, and R. A. Larsen. 1999. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28:82-92.
32. Rosas, A. L., J. D. Nosanchuk, B. L. Gomez, W. A. Edens, J. M. Henson, and A. Casadevall. 2000. Isolation and serological analyses of fungal melanins. J. Immunol. Methods 244:69-80.
33. Salas, S. D., J. E. Bennett, K. J. Kwong-Chung, J. R. Perfect, and P. R. Williamson. 1996. Effect of the laccase gene, CNLAC1, on virulence of Cryptococcus neoformans. J. Exp. Med. 184:377-386.
34. Sanati, H., S. A. Messer, M. Pfaller, M. Witt, R. Larsen, A. Espinel-Ingroff, and M. Ghannoum. 1996. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J. Clin. Microbiol. 34:1280-1282.
35. Wang, Y., and A. Casadevall. 1994. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob. Agents Chemother. 38:2648-2650.
36. Wang, Y., and A. Casadevall. 1996. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine. Antimicrob. Agents Chemother. 40:541-545.
37. Wheat, J., P. Marichal, H. Vanden Bossche, A. Le Monte, and P. Connolly. 1997. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob. Agents Chemother. 41:410-414.
38. Witt, M. D., R. J. Lewis, R. A. Larsen, E. N. Milefchik, M. A. Leal, R. H. Haubrich, J. A. Richie, J. E. Edwards, Jr., and M. A. Ghannoum. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin. Infect. Dis. 22:322-328.
39. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 104:234-240.